Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields

J Hematother. 1998 Jun;7(3):241-9. doi: 10.1089/scd.1.1998.7.241.

Abstract

The purpose of this study was to determine the effectiveness of second mobilization strategies in patients who yielded < 2.5 x 10(6) CD34+ PBSC/kg after initial mobilization. Repeat mobilization attempts were made with chemotherapy and G-CSF (n = 61) or G-CSF alone (n = 58) in patients who failed initial mobilization with chemotherapy and G-CSF (n = 92) or G-CSF alone (n = 27). A median of 0.27 x 10(6) CD34+ cells/kg per apheresis was collected after the second mobilization, compared with 0.16 with initial harvests (p = 0.0001). Forty-eight percent achieved a target CD34+ cell dose > or = 2.5 x 10(6)/kg when harvests from the first and second mobilizations were combined. Fifteen of 17 patients (88%) with > or = 1.5 x 10(6) CD34+ cells/kg harvested after first mobilization had > or = 2.5 x 10(6) CD34+ cells/kg collected when first and second harvests were combined, as compared with 42 of 102 (41%) achieving < 1.5 x 10(6) CD34+ cells/kg with first PBSC harvests (p = 0.0001). Second mobilizations with chemotherapy and G-CSF or G-CSF alone resulted in similar CD34+ cell yields. Toxicities of second mobilizations were comparable with those of first mobilizations. Seventy-nine patients (66%) received high-dose chemotherapy with PBSC support, with recovery of neutrophils and platelets in a median of 11 and 15 days, respectively. Transplant-related mortality was 4%, and event-free survival at 2 years was 0.34. It was concluded that second mobilization attempts in patients who fail to achieve > or = 2.5 x 10(6) CD34+ cells/kg on initial mobilization were successful in 48% of patients. G-CSF alone was as effective as chemotherapy plus G-CSF in mobilizing CD34+ cells and was associated with less morbidity.

MeSH terms

  • Adult
  • Antigens, CD / blood*
  • Antigens, CD34 / blood*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / blood
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Combined Modality Therapy
  • Cytapheresis / methods
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoietic Stem Cells / immunology
  • Hematopoietic Stem Cells / pathology*
  • Hodgkin Disease / therapy
  • Humans
  • Lymphoma / blood
  • Lymphoma / therapy*
  • Lymphoma, Non-Hodgkin / therapy
  • Male
  • Melphalan / therapeutic use*
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / therapy*
  • Neoplasm Staging

Substances

  • Antigens, CD
  • Antigens, CD34
  • Antineoplastic Agents
  • Granulocyte Colony-Stimulating Factor
  • Melphalan